Oligomeric compounds for the modulation of survivin expression

Details Oligomeric compounds for the modulation of survivin expression Oligomeric compounds for the modulation of survivin expression

2009-06-29

2010-06-22

Chong, Kimberly (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024500, C536S024310, C536S024100

Reexamination Certificate

active

07741309

ABSTRACT:
Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

REFERENCES:
patent: 5108921 (1992-04-01), Low et al.
patent: 5227400 (1993-07-01), Holton et al.
patent: 5248796 (1993-09-01), Chen et al.
patent: 5250683 (1993-10-01), Holton et al.
patent: 5254580 (1993-10-01), Chen et al.
patent: 5272171 (1993-12-01), Ueda et al.
patent: 5278324 (1994-01-01), Kingston et al.
patent: 5874416 (1999-02-01), Sheikhnejad
patent: 6077709 (2000-06-01), Bennett et al.
patent: 6117848 (2000-09-01), Monia et al.
patent: 6310044 (2001-10-01), Draper et al.
patent: 6509162 (2003-01-01), Altieri
patent: 6593091 (2003-07-01), Keys et al.
patent: 2002/0137708 (2002-09-01), Bennett et al.
patent: 2003/0032794 (2003-02-01), Koch et al.
patent: 2004/0241717 (2004-12-01), Hansen et al.
patent: 2004/0248840 (2004-12-01), Hansen et al.
patent: 2005/0014712 (2005-01-01), Hansen et al.
patent: 2006/0160095 (2006-07-01), Hayes et al.
patent: 0 253 739 (1989-10-01), None
patent: WO 92/09589 (1992-06-01), None
patent: WO 92/22651 (1992-12-01), None
patent: WO 93/18210 (1993-09-01), None
patent: WO 94/08003 (1994-04-01), None
patent: WO 94/28720 (1994-12-01), None
patent: WO 98/22589 (1998-05-01), None
patent: WO 98/49349 (1998-11-01), None
patent: WO 98/50540 (1998-11-01), None
patent: WO 99/02732 (1999-01-01), None
patent: WO 99/14226 (1999-03-01), None
patent: WO 99/22772 (1999-05-01), None
patent: WO 00/18781 (2000-04-01), None
patent: WO 00/56746 (2000-09-01), None
patent: WO 00/56748 (2000-09-01), None
patent: WO 00/66604 (2000-11-01), None
patent: WO 01/25248 (2001-04-01), None
patent: WO 01/46455 (2001-06-01), None
patent: WO 01/48190 (2001-07-01), None
patent: WO 01/57059 (2001-08-01), None
patent: WO 01/64741 (2001-09-01), None
patent: WO 02/28875 (2002-04-01), None
patent: WO 02/094250 (2002-11-01), None
patent: WO 03/006475 (2003-01-01), None
patent: WO 03/027244 (2003-04-01), None
patent: WO 03/091384 (2003-11-01), None
patent: WO 03/095467 (2003-11-01), None
patent: WO 2004/069991 (2004-08-01), None
Mita et al. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14(6):5000-5005.
Adida et al., “Anti-apoptosis gene, surviving, and prognosis of neuroblastoma,”Lancet, vol. 351, pp. 882-883 (1998).
Adida et al., “Expression and prognostic significance of survivin inde novoacute myeloid leukaemia,”Br. J. Haematol., vol. 111, pp. 196-203 (2000).
Adida et al., “Prognostic significance of survivin expression in diffuse large B-cell lymphomas,”Blood, vol. 96, No. 5, pp. 1921-1925 (2000).
Altieri, “Survivin, versatile modulation of cell division and apoptosis in cancer,”Oncogene, vol. 22, pp. 8551-8589 (2003).
Altmann et al., “Novel Chemistry,”Applied Antisense Oligonucleotide Technology, Chapter 4, Stein, Krieg, Wiley-Liss, pp. 73-107 (1998).
Ambrosini et al., “A novel anti-apoptosis gene,survivin, expressed in cancer and lymphoma,”Nat. Med., vol. 3, No. 8, pp. 917-921 (1997).
Ambrosini et al., “Induction of Apoptosis and Inhibition of Cell Proliferation bysurvivinGene Targeting,”J. Biol. Chem., vol. 273, No. 18, pp. 11177-11182 (1998).
Ansell et al., “Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma,”Leukemia, vol. 18, pp. 616-623 (2004).
Asanuma et al., “A Role for Survivin in Radioresistance of Pancreatic Cancer Cells,”Jpn. J. Cancer Res., vol. 93, pp. 1057-1062 (2002).
Ashkenazi et al., “Death Receptors: Signaling and Modulation,”Science, vol. 281, pp. 1305-1308 (1998).
Beaucage et al., “Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach,”Tetrahedron, vol. 48, No. 12, pp. 2223-2311 (1992).
Beaucage et al., “The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications,”Tetrahedron, vol. 49, No. 28, pp. 6123-6194 (1993).
Beltrami et al., “Acute Ablation of Survivin Uncovers p53-Dependent Mitotic Checkpoint Functions and Control of Mitochondrial Apoptosis,”J. Biol. Chem, vol. 279, pp. 2077-2084 (2003).
Bennett et al., “ras Oncogenes,”Antisense Therapeutics, pp. 16-27 (1996).
Blanc-Brude et al., “Therapeutic Targeting of the Survivin Pathway in Cancer: Initiation of Mitochondrial Apoptosis and Suppression of Tumor-associated Angiogenesis,”Clin. Cancer Res., vol. 9, pp. 2683-2692 (2003).
Brown et al., “In Oligonucleotides and Analogues. A Practical Approach,” Oxford: IRL 13-14 (1991).
Cao et al., “XIAP and Survivin as Therapeutic Targets for Radiation Sensitization in Preclinical Models of Lung Cancer,”Oncogene, vol. 23, pp. 1-6 (2004).
Carvalho et al., “Survivin is required for stable checkpoint activation in taxol-treated HeLa cells,”J. Cell. Sci., vol. 116, No. 14, pp. 2987-2998 (2003).
Chakravarti et al. “Quantitatively Determined Survivin Expression Levels Are of Prognostic Value in Human Gliomas,”J. Clin. Oncol. vol. 20, No. 4, pp. 1063-1068 (2002).
Chen et al., “Down-regulation of Survivin by Antisense Oligonucleotides Increases Apoptosis, Inhibits Cytokinesis and Anchorage-Independent Growth,”Neoplasia, vol. 2, No. 3, pp. 235-241 (2000).
Chen et al., “Survivin Enhances Aurora-B Kinase Activity and Localizes Aurora-B in Human Cells,”J. Biol. Chem., vol. 278, pp. 486-490 (2003).
Chin et al., “Essential role for oncogenic Ras in tumour maintenance,”Nature, vol. 400, pp. 468-472 (1999).
Chin et al., “On the Preparation and Utilization of Isolated and Purified Oligonucleotides,”Public Collection of the Kathrine R. Everett law Library of the University of North Carolina, Mar. 9, 2002 (on CD).
Cohen, “Caspases: the executioners of apoptosis,”Biochem J., vol. 326, pp. 1-16 (1997).
Conway et al., “Deficiency of Survivin in Transgenic Mice Exacerbates Fas-Induced Apoptosis Via Mitochondrial Pathways,”Gastroenterology, vol. 123, pp. 619-631 (2002).
Cowsert, “In vitro and in vivo activity of antisense inhibitors ofras: potential for clinical development,”Anti-Cancer Drug Design, vol. 12, pp. 359-371 (1997).
Crooke, R.M., “In Vitro Cellular Uptake, Distribution and Metabolism of Oligonucleotides,”Antisense Res. and Application131:103-140 1997).
Cunningham et al., “A phase I Trial of H-rasAntisense Oligonucleotide ISIS 2503 Administered as a Continuous Intravenous Infusion in Patients with Advanced Carcinoma,”Amer. Cancer Soc., vol. 92, pp. 1265-1271 (2001).
Dass, C.R., “Vehicles for oligonucleotide delivery to tumours,”J Pharm Pharmacol., vol. 54, pp. 3-27 (2002).
Dean et al., “Inhibition of Protein Knase C-α Expression in Human A549 Cells by Antisense Oligonucleotides Inhibits Induction of Intercellular Adhesion Molecule 1 (ICAM-1) mRNA by Phorbol Esters,”J. Biol. Chem., vol. 269, No. 23, pp. 16416-16424 (1994).
Evan et al., “Proliferation, cell cycle and apoptosis in cancer,”Nature, vol. 411, pp. 342-348 (2001).
Freier et al., “The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DANN:RNA duplexes,”N

Affiliated with

Also associated with

Rating

Oligomeric compounds for the modulation of survivin expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligomeric compounds for the modulation of survivin expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligomeric compounds for the modulation of survivin expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4202536